Pharmacosmos A/S

4 trials 4 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

19 Countries active

6 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 2 Phase II: 1 Phase I (Other): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Top indications

Iron deficiency 1 Small cell lung cancer extensive stage 1 Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome 1

Top IMPs

(S)-4,5-DIHYDRO-2-[2-HYDROXY-4-(3,6-DIOXAHEPTYLOXY)PHENYL]-4-METHYL-4-THIAZOLECARBOXYLIC ACID 1 FERRIC DERISOMALTOSE 1 SODIUM CHLORIDE 1 TOPOTECAN 1 TRILACICLIB DIHYDROCHLORIDE DIHYDRATE 1

All trials

4 total

A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people Recruiting

2025-525025-12-00 Phase I (Other) 1 country
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Phase III 12 countries FERRIC DERISOMALTOSE
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Phase III 8 countries SODIUM CHLORIDE; TOPOTECAN; TRILACICLIB DIHYDROCHLORIDE DIHYDRATE
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 Phase II 4 countries (S)-4,5-DIHYDRO-2-[2-HYDROXY-4-(3,6-DIOXAHEPTYLOXY)PHENYL]-4-METHYL-4-THIAZOLECA…

Showing 1–4 of 4 trials

← All sponsors A–Z